Immunotherapy of multiple sclerosis: where are we? Where should we go?
Martin
R
R
Neuroimmunology Branch, NINDS, National Institutes of Health, Building 10, Room 5B-16, 10 Center DR MSC 1400, Bethesda, MD 20892-1400, USA. martinr@ninds.nih.gov
Stürzebecher
C S
CS
McFarland
H F
HF
D015551:Autoimmunity; D005544:Forecasting; D020022:Genetic Predisposition to Disease; D006801:Humans; D016899:Interferon-beta / Q000627:therapeutic use; D018448:Models, Immunological; D009103:Multiple Sclerosis / Q000235:genetics / Q000276:immunology* / Q000628:therapy*; D017634:Self Tolerance; D013601:T-Lymphocytes / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D014409:Tumor Necrosis Factor-alpha; D016899:Interferon-beta